Plain-English translation of NCT05298995 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a treatment called GD2-CAR T cells for children and young adults with brain tumors that have come back or no longer respond to standard therapy. The treatment works by taking immune cells from your body, modifying them in the laboratory to recognize cancer cells, and then putting them back into your body through an infusion. The medication also includes a built-in safety switch that doctors can activate if serious side effects occur.
Brain tumors that return or resist standard chemotherapy and radiation are very difficult to treat, and children and young adults with these tumors need new treatment options. This medication represents a completely different approach — using the body's own immune system rather than traditional chemotherapy — to fight these hard-to-treat cancers.
You likely qualify if…
You likely don't qualify if…
First, doctors will remove immune cells from your blood through a procedure called leukapheresis, which takes a few hours. Your cells are then sent to a laboratory to be modified over several weeks. While waiting, you'll receive chemotherapy to prepare your body. Once the modified cells are ready, you'll receive them back as a single infusion in the hospital. You'll then be monitored closely for side effects and have regular follow-up visits for 5 years, with additional long-term follow-up for 15 years as required for gene therapy treatments.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy